Myriad Genetics Appoints Sam Raha as Chief Operating Officer
01 Novembro 2023 - 10:00AM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the appointment of Sam Raha
as Chief Operating Officer (COO), effective December 11, 2023.
Raha adds more than 25 years of general management, commercial,
and operations experience, deeply rooted in life sciences and
molecular diagnostics, to the team at Myriad Genetics. In his role
as COO, he will be responsible for driving the company’s lab
operations, customer service initiatives, and product development
innovations.
“Sam is an accomplished leader who understands how to build
teams and drive a patient-centric culture, with a proven ability to
define, execute and deliver profitable growth for companies within
the diagnostics space,” said Paul Diaz, President and CEO, Myriad
Genetics. “He will play an integral role in shaping Myriad’s
long-term growth strategy, while delivering new perspectives and
expertise to advance our current business initiatives, operational
excellence and profitability.”
Raha previously served as the President of Agilent’s Diagnostics
and Genomics Group where he was responsible for overall strategy
along with business and financial results. Prior to Agilent, he was
Vice President of Global Marketing at Illumina. He earned his MBA
from Santa Clara University and has an undergraduate degree in
molecular and cell biology from the University of California,
Berkeley.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to Mr. Raha’s expected contributions to the
company and Mr. Raha joining the company on December 11, 2023.
These “forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Media Contact:Glenn Farrell (385)
318-3718PR@myriad.com
Investor Contact: Matt Scalo(801)
584-3532IR@myriad.com
To view Sam Raha, Myriad Genetics Appoints Sam Raha
as Chief Operating Officer, please visit the
following
link: https://www.globenewswire.com/NewsRoom/AttachmentNg/f6b31029-47ff-47b4-a2d9-a7b04b514b04
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024